Quest Diagnostics Inc vs T Rowe Price Group Inc — how do they compare? Quest Diagnostics Inc trades at $237.5 (market cap $26.21B), while T Rowe Price Group Inc trades at $116.99 (market cap $24.26B). The key difference: Quest Diagnostics Inc and T Rowe Price Group Inc are close in size by market cap, and T Rowe Price Group Inc pays the higher dividend (4.57%). Which is the better fit depends on your goals.
| DGX | TROW | |
|---|---|---|
Market Cap | $26.21B | $24.26B |
Sector | Health | Financials |
52-Week High | $238.50 | $121.68 |
52-Week Low | $173.49 | $86.19 |
Enterprise Value | $31.97B | $21.46B |
Dividend Yield | 1.45% | 4.57% |
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →